Arena Pharmaceuticals Inc. (ARNA): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Arena Pharmaceuticals ( ARNA) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole was unchanged today. By the end of trading, Arena Pharmaceuticals fell 14 cents (-1.5%) to $8.64 on light volume. Throughout the day, 5.6 million shares of Arena Pharmaceuticals exchanged hands as compared to its average daily volume of 13 million shares. The stock ranged in price between $8.60-$8.92 after having opened the day at $8.83 as compared to the previous trading day's close of $8.77. Other companies within the Drugs industry that declined today were: Cell Therapeutics ( CTIC), down 24.9%, Geron Corporation ( GERN), down 11.3%, AEterna Zentaris ( AEZS), down 11.1%, and Tianyin Pharmaceutical ( TPI), down 10.5%.
  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena Pharmaceuticals has a market cap of $1.92 billion and is part of the health care sector. Shares are up 369% year to date as of the close of trading on Thursday. Currently there are two analysts that rate Arena Pharmaceuticals a buy, one analyst rates it a sell, and six rate it a hold.

TheStreet Ratings rates Arena Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been poor profit margins.

On the positive front, XenoPort ( XNPT), up 15.3%, Theratechnologies ( THER), up 15.2%, Delcath Systems ( DCTH), up 13.7%, and Oxygen Biotherapeutics ( OXBT), up 11.4%, were all gainers within the drugs industry with BioMarin Pharmaceuticals ( BMRN) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)

Allergan, USG Corp, Arena Pharmaceuticals: 'Mad Money' Lightning Round

These Stocks Have Changed Direction

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says